Analysts Offer Insights on Healthcare Companies: Xencor (XNCR), Argenica Therapeutics Ltd (AU:AGN) and Bio-Rad Laboratories (BIO)
Bio-Rad Upped by Citi to Buy; Charles River, Hologic Downgraded
Bio-Rad Laboratories Analyst Ratings
Citi Upgrades Bio-Rad Laboratories(BIO.US) to Buy Rating, Raises Target Price to $400
Nephron Initiates Bio-Rad Laboratories(BIO.US) With Buy Rating, Announces Target Price $390
Jefferies Maintains Bio-Rad Laboratories(BIO.US) With Hold Rating, Raises Target Price to $340
Bio-Rad Laboratories Analyst Ratings
RBC Capital Maintains Bio-Rad Laboratories(BIO.US) With Buy Rating, Maintains Target Price $401
Bio-Rad Laboratories (BIO) Receives a Buy From RBC Capital
Bio-Rad Laboratories Analyst Ratings
RBC Trims Price Target on Bio-Rad Laboratories to $401 From $402, Keeps Outperform Rating
RBC Capital Maintains Bio-Rad Laboratories(BIO.US) With Buy Rating, Cuts Target Price to $401
Citi Maintains Bio-Rad Laboratories(BIO.US) With Hold Rating, Raises Target Price to $350
Hold Rating Maintained for Bio-Rad Laboratories Amid Mixed Performance and Market Headwinds
Analysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (SNDX), Denali Therapeutics (DNLI) and Bio-Rad Laboratories (BIO)
Citi Upgrades Illumina, Quest, Agilent to Buy, Downgrades Avantor
RBC Trims Price Target on Bio-Rad Laboratories to $402 From $414, Keeps Outperform Rating
Bio-Rad Laboratories Analyst Ratings
UBS Adjusts Price Target on Bio-Rad Laboratories to $385 From $420, Maintains Buy Rating
Bio-Rad Laboratories Analyst Ratings